1
|
Wang L, Ren M, Chen C, Yang X, Zhang C, Gao J, Wang J, Yang C. Cold atmospheric plasma in combination with laser therapy provides a window for the treatment of hyperproliferative skin disease. Photodiagnosis Photodyn Ther 2024; 48:104243. [PMID: 38862086 DOI: 10.1016/j.pdpdt.2024.104243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 04/09/2024] [Accepted: 06/07/2024] [Indexed: 06/13/2024]
Abstract
Modern medical understanding suggests that hyperproliferative skin diseases (HSDs) are complex syndromes characterized by localized hypertrophy or hyperplasia and infiltration of inflammatory cells. Various treatments, including systemic and topical pharmacotherapy, laser interventions, photodynamic therapy, and surgery, have been proposed for managing HSDs. However, challenges such as wound healing and recurrence after laser treatment have hindered the effectiveness of laser therapy. To overcome these challenges, we conducted a study combining laser therapy with cold atmospheric plasma (CAP) for the treatment of HSDs. Seven patients with different forms of HSDs, who had not responded well to conventional treatments, were enrolled in the study. These HSDs included cases of erythroplasia of Queyrat, pyoderma gangrenosum, keloids and hypertrophic scars, cellulitis, cutaneous lichen planus, and verruca vulgaris. Laser therapy was performed to remove the hyperplastic skin lesions, followed immediately by daily CAP treatment. The results were promising, with all patients successfully treated and no recurrence observed during the follow-up periods. The combined application of CAP and laser therapy proved to be an effective and complementary strategy for managing HSDs. This innovative approach provide evidence for addressing the limitation of laser therapy by utilizing CAP to promote wound healing and mitigate inflammatory responses. Chinese Clinical Trial Registry (ChiCTR2300069993).
Collapse
Affiliation(s)
- Liyun Wang
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Miaomiao Ren
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Cheng Chen
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Xingyu Yang
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Chenchen Zhang
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Jing Gao
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Jingwen Wang
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China
| | - Chunjun Yang
- Department of Dermatology and Venereology, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China; Joint Laboratory for Plasma Clinical Applications, the Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230601, China.
| |
Collapse
|
2
|
Khachemoune A, Juan HY, Singh R. Shedding new light on actinic keratoses and squamous cell carcinoma in situ. JAAPA 2024; 37:1-6. [PMID: 38128142 DOI: 10.1097/01.jaa.0000995696.23729.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
ABSTRACT Cutaneous squamous cell carcinoma can arise from various premalignant lesions such as actinic keratosis, Bowen disease, and premalignant genital squamous cell lesions. Identification and treatment can prevent malignant transformation and death. This article describes the causes, epidemiology, and characteristics of suspicious premalignant squamous cell lesions so that clinicians can identify these lesions and refer patients for specialist treatment as appropriate.
Collapse
Affiliation(s)
- Amor Khachemoune
- Amor Khachemoune practices at the Brooklyn (N.Y.) Veterans Affairs Medical Center and SUNY Downstate's Department of Dermatology, also in Brooklyn, N.Y. Hui Yu Juan is a fourth-year medical student at the Virginia Commonwealth University School of Medicine in Richmond, Va. At the time this article was written, Rohan Singh was a third-year medical student at the University of Maryland School of Medicine in Baltimore, Md. Dr. Singh now is a first-year resident at the University of Maryland Medical Center's Department of Internal Medicine. The authors have disclosed no potential conflicts of interest, financial or otherwise
| | | | | |
Collapse
|